1. Thariat J, Hannoun-Levi JM, Sun Myint A, Vuong T, Gérard JP. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol. (2013) 10(1):52-60.
2. Loeffler JS, Durante M. Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol. (2013) 10(7):411-24.
3. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes HR, Timmerman RD. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. (2010) 7(1):44-54.
4. Harrington K, Jankowska P, Hingorani M. Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol (R Coll Radiol). (2007) 19(8):561-71.
5. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. (2008) 8(3):193-204.
6. Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol. (2006) 16(1):59-64.
7. Kelley K, Knisely J, Symons M, Ruggieri R. Radioresistance of Brain Tumors. Cancers (Basel). (2016) 30;8(4):42.
8. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. (2018) 15(2):81-94.
9. Boustani J, Grapin M, Laurent PA, Apetoh L, Mirjolet C. The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. Cancers (Basel). (2019) 20;11(6):860.
10. Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. (2015) 12(9):527-40.
11. Stock GT, Bonadio RRCC, de Castro G Junior. De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease. Curr Opin Oncol. (2018) 30(3):146-151.
12. Yasui H, Iizuka D, Hiraoka W, Kuwabara M, Matsuda A, Inanami O. Nucleoside analogs as a radiosensitizer modulating DNA repair, cell cycle checkpoints, and apoptosis. Nucleosides Nucleotides Nucleic Acids. (2020) 39(1-3):439-452.
13. Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. (2015) 66:129-43.
14. O'Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. (2015) 19;60(4):547-60
15. Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. (2016) 16(1):35-42.
16. Carrassa L, Damia G. DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy. Cancer Treat Rev. (2017) 60:139-151.
17. Burnstock G. The therapeutic potential of purinergic signalling. Biochem Pharmacol. (2018) 151:157-165.
18. Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene. (2017) 19;36(3):293-303.
19. Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer. (2018) 18(10):601-618.
20. Gao ZG, Jacobson KA. A(2B) Adenosine Receptor and Cancer. Int J Mol Sci. (2019) 17;20(20):5139.
21. Nishimaki N, Tsukimoto M, Kitami A, Kojima S. Autocrine regulation of γ-irradiation-induced DNA damage response via extracellular nucleotides-mediated activation of P2Y6 and P2Y12 receptors. DNA Repair (Amst). (2012) 1;11(8):657-65.
22. Ohshima Y, Tsukimoto M, Takenouchi T, Harada H, Suzuki A, Sato M, Kitani H, Kojima S. gamma-Irradiation induces P2X(7) receptor-dependent ATP release from B16 melanoma cells. Biochim Biophys Acta. (2010) 1800(1):40-6.
23. Ohshima Y, Kitami A, Kawano A, Tsukimoto M, Kojima S. Induction of extracellular ATP mediates increase in intracellular thioredoxin in RAW264.7 cells exposed to low-dose γ-rays. Free Radic Biol Med. (2011) 15;51(6):1240-8.
24. Ohsaki A, Miyano Y, Tanaka R, Tanuma SI, Kojima S, Tsukimoto M. A Novel Mechanism of γ-Irradiation-Induced IL-6 Production Mediated by P2Y11 Receptor in Epidermal Keratinocytes. Biol Pharm Bull. (2018) 1;41(6):925-936.
25. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. (2018) 12(1):3-20.
26. Vanan I, Dong Z, Tosti E, Warshaw G, Symons M, Ruggieri R. Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion. Cell Mol Neurobiol. (2012) 32(7):1199-208.
27. Tie-Cheng Liu, Xin Jin, Yan Wang, Ke Wang. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am J Cancer Res. (2017) 7(2): 187–202.
28. Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol. (2016) 6;11(1):115.
29. Pavlopoulou A, Oktay Y, Vougas K, Louka M, Vorgias CE, Georgakilas AG. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells. Cancer Lett. (2016) 1;380(2):485-93.
30. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. (2000) 13;103(2):211-25.
31. Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiother Oncol. (2013) 108(3):370-7.
32. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer. (2008) 12;7:69.
33. Li Z, Hosoi Y, Cai K, Tanno Y, Matsumoto Y, Enomoto A, Morita A, Nakagawa K, Miyagawa K. Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation. Biochem Biophys Res Commun. (2006) 10;341(2):363-8.
34. Tamaishi N, Tsukimoto M, Kitami A, Kojima S P2Y6 receptors and ADAM17 mediate low-dose gamma-ray-induced focus formation (activation) of EGF receptor. Radiat Res. (2011) 175(2):193-200.
35. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. (2008) 7(9):759-70.
36. Dittmann K, Mayer C, Rodemann HP. Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol. (2010) 186(1):1-6.
37. Nishino K, Tanamachi K, Nakanishi Y, Ide S, Kojima S, Tanuma S, Tsukimoto M. Radiosensitizing effect of TRPV1 channel inhibitors in cancer cells. Biol Pharm Bull. (2016) 1;39(7):1224-30.
38. Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ, Darcy PK. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A. (2013) 3;110(36):14711-6.
39. Koszałka P, Gołuńska M, Stanisławowski M, Urban A, Stasiłojć G, Majewski M, Wierzbicki P, Składanowski AC, Bigda J. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis. Int J Biochem Cell Biol. (2015) 69:1-10.
40. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. (2010) 26;107(4):1547-52.
41. Terp MG, Olesen KA, Arnspang EC, Lund RR, Lagerholm BC, Ditzel HJ,Leth-Larsen R. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol. (2013) 15;191(8):4165-73.
42. Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le Page C, Provencher D, Mes-Masson AM, Stagg J. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. (2015) 1;75(21):4494-503.
43. Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard K, Caramia F, Haibe-Kains B, Stagg J, Khanna KK, Loi S, Smyth MJ. Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. Cancer Res. (2016) 1;76(15):4372-82.
44. Wojnarowicz PM, Breznan A, Arcand SL, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer. (2008) 18(5):963-75.
45. Xiang HJ, Liu ZC, Wang DS, Chen Y, Yang YL, Dou KF. Adenosine A(2b) receptor is highly expressed in human hepatocellular carcinoma. Hepatol Res. (2006) 36(1):56-60.
46. Ma DF, Kondo T, Nakazawa T, Niu DF, Mochizuki K, Kawasaki T, Yamane T, Katoh R. Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol. (2010) 41(11):1550-7.
47. Kasama H, Sakamoto Y, Kasamatsu A, Okamoto A, Koyama T, Minakawa Y, Ogawara K, Yokoe H, Shiiba M, Tanzawa H, Uzawa K. Adenosine A2b receptor promotes progression of human oral cancer. BMC Cancer. (2015) 31;15:563.
48. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol. (2012) 1;188(1):198-205.
49. Ide S, Nishimaki N, Tsukimoto M, Kojima S. Purine receptor P2Y6 mediates cellular response to γ-ray-induced DNA damage. J Toxicol Sci. (2014) 39(1):15-23.
50. Ram PT, Iyengar R. G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. Oncogene. (2001) 26;20(13):1601-6.
51. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol. (2005) 76(2):157-61.
52. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ,Kehlbach R, Rodemann HP. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. (2005) 2;280(35):31182-9.
53. Pannunzio NR, Watanabe G, Lieber MR. Nonhomologous DNA end-joining for repair of DNA double-strand breaks. J Biol Chem. (2018) 6;293(27):10512-10523.
54. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, Belinsky SA. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. (2011) 15;71(8):3087-97.
55. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. (2017) 14(9):549-561.
56. Tanaka Y, Kitabatake K, Abe R, Tsukimoto M. Involvement of A2B receptor in DNA damage response and radiosensitizinge effect of A2B receptor antagonists on mouse B16 melanoma. Biol Pharm Bull. (2020) 1;43(3):516-525.
57. Sek K, Mølck C, Stewart GD, Kats L, Darcy PK, Beavis PA. Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci. (2018) 2;19(12):3837.
58. Perez-Aso M, Mediero A, Low YC, Levine J, Cronstein BN. Adenosine A2A receptor plays an important role in radiation-induced dermal injury. FASEB J. (2016) 30(1):457-65.
59. Guerrero A. A2A Adenosine receptor agonists and their potential therapeutic applications. an update. Curr Med Chem. (2018) 25(30):3597-3612.
60. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev. (2017) 276(1):121-144.
61. Kaji W, Tanaka S, Tsukimoto M, Kojima S. Adenosine A(2B) receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells. J Toxicol Sci. (2014) 39(2):191-8.
62. Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I, Dikov MM, Feoktistov I. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol. (2011) 1;187(11):6120-9.
63. De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. (2019) 21;5(1):13.
64. Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. (2016) 16(1):20-33.
65. Burnstock G. Purinergic Signalling: Therapeutic Developments. Front Pharmacol. (2017) 25;8:661.
66. Tsukimoto M, Homma T, Mutou Y, Kojima S. 0.5 Gy gamma radiation suppresses production of TNF-alpha through up-regulation of MKP-1 in mouse macrophage RAW264.7 cells. Radiat Res. (2009) 171(2):219-24.
67. Shinohara Y, Tsukimoto M. Adenine Nucleotides Attenuate Murine T Cell Activation Induced by Concanavalin A or T Cell Receptor Stimulation. Front Pharmacol. (2018) 10;8:986.
68. Shinohara Y, Tsukimoto M. Guanine and inosine nucleotides/nucleosides suppress murine T cell activation. Biochem Biophys Res Commun. (2018) 15;498(4):764-768.
69. Nakamura AJ, Rao VA, Pommier Y, Bonner WM. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle. (2010) 15;9(2):389-97.
70. Ward IM, Minn K, Jorda KG, Chen J. Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX. J Biol Chem. (2003) 30;278(22):19579-82.
71. Sesma JI, Kreda SM, Steinckwich-Besancon N, Dang H, García-Mata R, Harden TK, Lazarowski ER. The UDP-sugar-sensing P2Y(14) receptor promotes Rho-mediated signaling and chemotaxis in human neutrophils. Am J Physiol Cell Physiol. (2012) 1;303(5):C490-8.
72. Philchenkov A. Radiation-induced cell death: signaling and pharmacological modulation. Crit Rev Oncog. (2018) 23(1-2):13-37.
73. Di Virgilio F, Chiozzi P, Falzoni S, Ferrari D, Sanz JM, Venketaraman V, Baricordi OR. Cytolytic P2X purinoceptors. Cell Death Differ. (1998) 5(3):191-9.
74. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR, Pinton P, Rizzuto R, Di Virgilio F. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. (2005) 16(7):3260-72.
75. Molkentine JM, Fujimoto TN, Horvath TD, Grossberg AJ, Garcia CJG, Deorukhkar A, de la Cruz Bonilla M, Lin D, Samuel ELG, Chan WK, Lorenzi PL, Piwnica-Worms H, Dantzer R, Tour JM, Mason KA, Taniguchi CM. Enteral activation of WR-2721 mediates radioprotection and improved survival from lethal fractionated radiation. Sci Rep. (2019) 13;9(1):1949.
76. Puri RN, Colman RW. ADP-induced platelet activation. Crit Rev Biochem Mol Biol. (1997) 32(6):437-502.
77. Agteresch HJ, Dagnelie PC, van den Berg JW, Wilson JH. Adenosine triphosphate: established and potential clinical applications. Drugs. (1999) 58(2):211-32.
78. Aho J, Helenius M, Vattulainen-Collanus S, Alastalo TP, Koskenvuo J. Extracellular ATP protects endothelial cells against DNA damage. Purinergic Signal. (2016) 12(3):575-81.
79. Satoh E, Tsukimoto M, Kojima S. Involvement of P2Y receptors in the protective effect of ATP towards the cell damage in HaCaT cells exposed to H2O2. J Toxicol Sci. (2011) 36(6):741-50.
80. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. (2017) 15(11):1331-1345.
81. Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, Park HG, Han SI, Kang HS. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. (2017) 30;16(1):10.
82. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. (2009) 22;461(7267):1071-8.
83. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. (2007) 10;26(56):7773-9.
84. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. (2005) 14;434(7035):864-70.
85. Squatrito M, Holland EC. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res. (2011) 15;71(18):5945-9.
86. Bours MJ, Dagnelie PC, Giuliani AL, Wesselius A, Di Virgilio F. P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation. Front Biosci (Schol Ed). (2011) 1;3:1443-56.
87. Seol HJ, Yoo HY, Jin J, Joo KM, Kong DS, Yoon SJ, Yang H, Kang W, Lim DH, Park K, Kim JH, Lee JI, Nam DH. Prognostic implications of the DNA damage response pathway in glioblastoma. Oncol Rep. (2011) 26(2):423-30.
88. Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. (2012) 920:613-26.
89. Moncharmont C, Levy A, Guy JB, Falk AT, Guilbert M, Trone JC, Alphonse G, Gilormini M, Ardail D, Toillon RA, Rodriguez-Lafrasse C, Magné N.Radiation-enhanced cell migration/invasion process: a review. Crit Rev Oncol Hematol. (2014) 92(2):133-42.
90. Su WH, Chuang PC, Huang EY, Yang KD. Radiation-induced increase in cell migration and metastatic potential of cervical cancer cells operates via the K-Ras pathway. Am J Pathol. (2012) 180(2):862-71.
91. Ogata T, Teshima T, Kagawa K, Hishikawa Y, Takahashi Y, Kawaguchi A, Suzumoto Y, Nojima K, Furusawa Y, Matsuura N. Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res. (2005) 1;65(1):113-20.
92. Fujita M, Otsuka Y, Imadome K, Endo S, Yamada S, Imai T. Carbon-ion radiation enhances migration ability and invasiveness of the pancreatic cancer cell, PANC-1, in vitro. Cancer Sci. 2012 Apr;103(4):677-83.
93. Edlund S, Landström M, Heldin CH, Aspenström P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell. (2002) 13(3):902-14.
94. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. (2007) 14(7):1315-23.
95. Sepúlveda C, Palomo I, Fuentes E. Role of adenosine A2b receptor overexpression in tumor progression. Life Sci. (2016) 1;166:92-99.
96. Yan A, Joachims ML, Thompson LF, Miller AD, Canoll PD, Bynoe MS. CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A(2B) Adenosine Receptor Signaling. J Neurosci. (2019) 29;39(22):4387-4402.
97. Kiseleva LN, Kartashev AV, Vartanyan NL, Pinevich AA, Samoilovich MP. Chracteristics of A172 and T98G cell lines. Tsitologiia. (2016) 58(5):349-55.
98. Xu S, Shao QQ, Sun JT, Yang N, Xie Q, Wang DH, Huang QB, Huang B, Wang XY, Li XG, Qu X. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol. (2013) 15(9):1160-72.
99. Shali S, Yu J, Zhang X, Wang X, Jin Y, Su M, Liao X, Yu J, Zhi X, Zhou P. Ecto-5'-nucleotidase (CD73) is a potential target of hepatocellular carcinoma. J Cell Physiol. (2019) 234(7):10248-10259.
100. Burnstock G. Purinergic signalling. Br J Pharmacol. (2006) 147 Suppl 1(Suppl 1):S172-81.
101. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta. (2008) 1783(5):673-94.
102. Tian Y, Piras BA, Kron IL, French BA, Yang Z. Adenosine 2B Receptor Activation Reduces Myocardial Reperfusion Injury by Promoting Anti-Inflammatory Macrophages Differentiation via PI3K/Akt Pathway. Oxid Med Cell Longev. (2015) 2015:585297.
103. Richard CL, Tan EY, Blay J. Adenosine upregulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1alpha. Int J Cancer. (2006) 1;119(9):2044-53.
104. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. (2009) 5(8):1145-68.
105. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol. (2007) 213(2):374-83.
106. Mjaatvedt CH, Markwald RR. Induction of an epithelial-mesenchymal transition by an in vivo adheron-like complex. Dev Biol. (1989) 136(1):118-28.
107. Washiya K, Sasaki R, Nakanishi Y, Kitabatake K, Nishino K, Tanuma S, Kojima S, Tsukimoto M. Involvement of TRPV1 and TRPV4 channels in enhancement of metastatic ability induced by γ-irradiation in human lung cancer A549 cells. BPB reports. (2020) 3, 50-55.
108. Ohsaki A., Tanuma S., Tsukimoto M. TRPV4 Channel-Regulated ATP Release Contributes to γ-Irradiation-Induced Production of IL-6 and IL-8 in Epidermal Keratinocytes. Biol Pharm Bull. (2018) 41(10):1620-1626.
109. Takai E, Tsukimoto M, Harada H, Sawada K, Moriyama Y, Kojima S. Autocrine regulation of TGF-β1-induced cell migration by exocytosis of ATP and activation of P2 receptors in human lung cancer cells. J Cell Sci. (2012) 1;125(Pt 21):5051-60.
110. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, D'Atri S. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol. (2004) 66(3):478-91.
111. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol. (2010) 11(3):220-8.
112. Seitz L, Jin L, Leleti M, Ashok D, Jeffrey J, Rieger A, Tiessen RG, Arold G, Tan JBL, Powers JP, Walters MJ, Karakunnel J. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest New Drugs. (2019) 37(4):711-721.
113. Nakamura K, Konishi K, Komatsu T, Sasaki T, Shikama N. Patterns of radiotherapy infrastructure in Japan and in other countries with well-developed radiotherapy infrastructures. Jpn J Clin Oncol. (2018) 1;48(5):476-479.